The lower blood uptake observed in immunocompromised mice with U87-MGvIII tumors, compared to immunocompetent mice with GL261 tumors, may be attributed to the absence of PD-L1-expressing peripheral mononuclear cells, leading to more 89Zr-DFO-Atezolizumab being available for binding to tumor epitopes. This evidence concerns the gene CD274 and neoplasm.